Home/Filings/4/0000950103-21-007078
4//SEC Filing

Reddoch James F. 4

Accession 0000950103-21-007078

CIK 0001802768other

Filed

May 10, 8:00 PM ET

Accepted

May 11, 9:06 PM ET

Size

9.4 KB

Accession

0000950103-21-007078

Insider Transaction Report

Form 4
Period: 2021-05-07
Reddoch James F.
EVP, Research & Investments
Transactions
  • Conversion

    Class A Ordinary Shares

    2021-05-07+1,320,8001,520,800 total(indirect: By LLC)
  • Conversion

    LP interests in RPI US Partners 2019, LP

    2021-05-07132,080486,398 total(indirect: By LLC)
    Exercise: $0.00Class A Ordinary Shares (1,320,800 underlying)
Holdings
  • Class A Ordinary Shares

    (indirect: By IRA)
    25,030
Footnotes (3)
  • [F1]These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with the exchange.
  • [F2]Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value.
  • [F3]The Reporting Person has agreed to retain and not sell 485,118 RPI US LP Interests convertible into 4,851,180 Class A Ordinary Shares before February 2025 pursuant to an agreement by and between the Reporting Person and RP Management, LLC. This restriction is waivable under certain circumstances.

Issuer

Royalty Pharma plc

CIK 0001802768

Entity typeother

Related Parties

1
  • filerCIK 0001814872

Filing Metadata

Form type
4
Filed
May 10, 8:00 PM ET
Accepted
May 11, 9:06 PM ET
Size
9.4 KB